Tag Archives: Professor Sam Schulman

Boehringer Ingelheim announced new data analyses show positive treatment effect of Pradaxa® (dabigatran etexilate) in patients with acute deep vein thrombosis or pulmonary embolism

For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release